Implications of first-line adjuvant treatment with aromatase inhibitors in recurrent metastatic breast cancer

Lisa E. Sokolowicz, William J. Gradishar*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The role of adjuvant tamoxifen therapy has gone unchallenged until recently. With the introduction of the selective aromatase inhibitors (AIs), the paradigm for treatment of hormone receptor-positive breast cancer in postmenopausal women is changing. New data from randomized clinical trials have shown the impact of the use of an AI compared with tamoxifen or in sequence with tamoxifen. This review will emphasize some of the highlights from these data sets and the limitations of our current knowledge. Finally, we will discuss the implications of the use of nonselective AIs in the adjuvant setting for the patient who develops recurrent metastatic disease.

Original languageEnglish (US)
Pages (from-to)S24-S30
JournalClinical breast cancer
Volume5
Issue numberSUPPL. 1
DOIs
StatePublished - Sep 2004

Keywords

  • Anastrozole
  • Exemestane
  • Fulvestrant
  • Letrozole
  • Sequential therapy
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Implications of first-line adjuvant treatment with aromatase inhibitors in recurrent metastatic breast cancer'. Together they form a unique fingerprint.

Cite this